A Randomized, Double‐Blind, Placebo‐Controlled Multicenter Study of Adalimumab in Pediatric Patients With Enthesitis‐Related Arthritis

A Randomized, Double‐Blind, Placebo‐Controlled Multicenter Study of Adalimumab in Pediatric Patients With Enthesitis‐Related Arthritis

Objective Enthesitis‐related arthritis (ERA) is a juvenile idiopathic arthritis (JIA) category, primarily affecting entheses and peripheral joints. This study evaluated efficacy, safety, and pharmacokinetics of adalimumab versus placebo in patients with ERA. Methods This is a phase III, multicenter,...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Arthritis care & research (2010) 2015-11, Vol.67 (11), p.1503-1512
Hauptverfasser: Burgos‐Vargas, Rubén, Tse, Shirley M. L., Horneff, Gerd, Pangan, Aileen L., Kalabic, Jasmina, Goss, Sandra, Unnebrink, Kristina, Anderson, Jaclyn K.
Format: Artikel
Sprache:eng
Schlagworte:
Adalimumab - therapeutic use
Adolescent
Antirheumatic Agents - therapeutic use
Arthritis, Juvenile - diagnosis
Arthritis, Juvenile - drug therapy
Child
Double-Blind Method
Female
Humans
Male
Pediatric Rheumatology
Treatment Outcome
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Objective Enthesitis‐related arthritis (ERA) is a juvenile idiopathic arthritis (JIA) category, primarily affecting entheses and peripheral joints. This study evaluated efficacy, safety, and pharmacokinetics of adalimumab versus placebo in patients with ERA. Methods This is a phase III, multicenter, randomized double‐blind study in patients ages ≥6 to
ISSN:2151-464X
2151-4658
DOI:10.1002/acr.22657